The GRK6 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the GRK6 gene in HeLa cells. This polyclonal format offers a heterogeneous pool of edited cells, enabling robust loss-of-function analysis while minimizing clonal selection biases. The CRISPR/Cas9-mediated gene editing provides a powerful tool for dissecting G protein-coupled receptor (GPCR) desensitization and related signaling pathways.
HeLa cells are an immortalized human cervical adenocarcinoma epithelial line extensively used in biomedical research. Their well-characterized signaling networks, including diverse GPCR expression, make them an ideal host for studying kinase-dependent receptor regulation. The GRK6 knockout in this background allows investigation of receptor desensitization mechanisms in a cancer-relevant cellular context.
GRK6 encodes a serine/threonine kinase that phosphorylates activated GPCRs, promoting recruitment of beta-arrestins, which sterically block G protein coupling and facilitate receptor internalization via clathrin-coated pits. Upstream, GRK6 is regulated by activated GPCRs, G beta-gamma subunits, PIP2, and protein kinase C. Downstream, it modulates beta-arrestin?Cdependent pathways, including MAPK/ERK, p38 MAPK, and chemokine signaling, and also targets non-receptor substrates such as dopamine receptors. Key interacting proteins include caveolin, heat shock protein 90, 14-3-3 proteins, and phospholipids, which influence its localization and activity. This positions GRK6 at a critical junction controlling both receptor desensitization and downstream signaling cascades.
In the HeLa carcinoma model, GRK6 knockout enables precise examination of how loss of kinase function alters GPCR-mediated signaling, cell migration, and chemokine responsiveness. HeLa cells endogenously express components of the clathrin-mediated endocytosis machinery and various GPCRs, allowing researchers to assess GRK6??s role in receptor internalization and signal termination under physiologically relevant conditions. This system is particularly useful for exploring GRK6??s contributions to cancer cell signaling, where dysregulated GPCR activity influences proliferation and metastasis.
This knockout model supports diverse functional assays, including Western blotting for phospho-GPCR detection, flow cytometry for receptor internalization kinetics, cAMP and calcium flux measurements, co-immunoprecipitation for GRK6-substrate interactions, and migration or chemotaxis assays. These approaches facilitate research into GPCR-targeted drug discovery, Parkinson??s disease pathology, and cancer signal transduction. For further information, please contact Ascent Research.
